NAGE Stock Analysis: Buy, Sell, or Hold?
NAGE - Niagen Bioscience, Inc. Common Stock
$5.99
0.00 (0.00%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 03, 2026
Get Alerted When NAGE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NAGE shows positive signals but monitor for confirmation. Market pricing in 6.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NAGE shows positive signals but monitor for confirmation. Market pricing in 6.2% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.17
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$7.56
20.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NAGE is currently trading at $5.99, which is considered oversold relative to its 30-day fair value range of $6.15 to $6.59. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.0) compared to its historical average (29.1). Remarkably, the market is currently pricing in an annual earnings decline of 6.2% over the next few years. This pessimistic expectation contrasts with the company's recent 150.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $5.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NAGE has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.80 (+163.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $5.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NAGE has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.80 (+163.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$6.15 -
$6.59
Company Quality Score
57/100
(HOLD)
Options IV Signal
20th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 20th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 163.8% below Wall St target ($15.80)
Fair Price Analysis
30-Day Fair Range
$6.15 -
$6.59
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.67
(11.1%)
Support & Resistance Levels
Support Level
$5.91
Resistance Level
$6.41
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
23.96
Wall Street Target
$15.80
(+163.8%)
Revenue Growth (YoY)
32.9%
Earnings Growth (YoY)
150.0%
Profit Margin
16.4%
Valuation Discount vs History
-6.2% cheaper
PE vs Historical
24.0 vs 29.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.2%
(market-implied from PE analysis)
1-Year Target
$5.62
(-6%)
2-Year Target
$5.27
(-12%)
3-Year Target
$4.94
(-18%)
3-Yr Target (if PE normalizes)
(PE: 24→29)
$6.00
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.0, Growth: 38.9%)
$16.05
(+168%)
Base:
(SPY PE: 22.3, Growth: 38.9%)
$14.94
(+149%)
Bear:
(PE: 19.0, Growth: 38.9%)
$12.70
(+112%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 26.00 | Current EPS (TTM): $0.24
Bull Case
$7.15
(+19%)
Analyst growth 4.2%, PE expands to 28.6
Base Case
$6.50
(+9%)
Market implied 4.2%, PE stable at 26.0
Bear Case
$4.24
(-29%)
Severe decline -20.0%, PE contracts to 22.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.0 to 29.1
Stabilization Target:
$7.28
(+21.5%)
PE Expansion Potential:
+21.5%
Last updated: January 30, 2026 5:44 PM ET
Data refreshes hourly during market hours. Next update: 6:44 PM
Data refreshes hourly during market hours. Next update: 6:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAGE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$210 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
Advanced NAGE Option Strategies
Professional options setups generated by AI based on today's NAGE price and gamma walls.
